Monograph Details
|
|
Cardiovascular System
> Edema
|
|
DYAZIDE |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
K+-sparing + thiazide. |
| Generic Name |
|
Triamterene 37.5mg, hydrochlorothiazide 25mg; caps. |
| Indications |
|
Edema. |
| Children |
|
Not recommended. |
| Adults |
|
1–2 caps once daily. |
| Contraindications |
|
Hyperkalemia. Renal impairment. Anuria. Sulfonamide allergy. Concomitant potassium or K+-sparing diuretics. |
| Precautions |
|
Diabetes. Acidosis predisposition. Electrolyte imbalance. Hypochloremia with metabolic alkalosis. Excess diuresis. History of renal stones. Gout. Surgery. SLE. Monitor electrolytes, renal function. Discontinue if serum potassium >5.5mEq/L or <3mEq/L. Hepatic impairment: monitor for hepatic coma, if confusion increases, discontinue for a few days. Severely ill. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Digoxin, lithium toxicity. Hyperkalemia more likely with ACE inhibitors, parenteral penicillin G. Hypokalemia with ACTH, corticosteroids, amphotericin B. Hyponatremia with sulfonylureas. NSAIDs may cause renal failure. Adjust antidiabetic, antigout medications. May potentiate nondepolarizing muscle relaxants, antihypertensives. Antagonizes oral anticoagulants, methenamine. May interfere with parathyroid tests. |
| Adverse Reactions |
|
Drowsiness, muscle cramps, weakness, headache, GI disturbances, dizziness, impotence, arrhythmias, hypotension, dry mouth, urine discoloration. |
| How Supplied |
|
Caps—100, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
